Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:37PM ET
150.04
Dollar change
-4.35
Percentage change
-2.82
%
Index- P/E- EPS (ttm)-3.56 Insider Own0.53% Shs Outstand125.79M Perf Week2.33%
Market Cap18.90B Forward P/E- EPS next Y-1.90 Insider Trans-10.32% Shs Float125.27M Perf Month-3.34%
Income-440.24M PEG- EPS next Q-1.13 Inst Own93.69% Short Float2.14% Perf Quarter-23.67%
Sales1.83B P/S10.34 EPS this Y-13.22% Inst Trans0.95% Short Ratio3.14 Perf Half Y-15.16%
Book/sh-1.75 P/B- EPS next Y52.27% ROA-11.94% Short Interest2.69M Perf Year-21.24%
Cash/sh19.37 P/C7.75 EPS next 5Y- ROE-1500.66% 52W Range143.52 - 218.88 Perf YTD-21.61%
Dividend Est.- P/FCF450.48 EPS past 5Y14.18% ROI-18.61% 52W High-31.45% Beta0.39
Dividend TTM- Quick Ratio2.99 Sales past 5Y97.61% Gross Margin83.02% 52W Low4.54% ATR (14)4.64
Dividend Ex-Date- Current Ratio3.08 EPS Y/Y TTM61.98% Oper. Margin-15.43% RSI (14)44.30 Volatility3.05% 2.87%
Employees2100 Debt/Eq- Sales Y/Y TTM76.23% Profit Margin-24.08% Recom1.80 Target Price218.67
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q34.79% Payout- Rel Volume0.28 Prev Close154.39
Sales Surprise0.64% EPS Surprise7.28% Sales Q/Q31.25% EarningsFeb 15 BMO Avg Volume856.65K Price150.04
SMA200.37% SMA50-7.28% SMA200-15.53% Trades Volume225,751 Change-2.82%
Date Action Analyst Rating Change Price Target Change
Feb-16-24Downgrade Goldman Buy → Neutral $173
Feb-15-24Initiated Wolfe Research Peer Perform
Dec-08-23Initiated Wells Fargo Equal Weight $171
Dec-08-23Initiated Wells Fargo Equal Weight
Oct-11-23Downgrade Oppenheimer Outperform → Perform
Sep-29-23Initiated Raymond James Outperform $208
May-05-23Upgrade BMO Capital Markets Market Perform → Outperform $200 → $250
Apr-26-23Initiated SMBC Nikko Neutral $220
Mar-21-23Initiated Bernstein Outperform $243
Jan-18-23Initiated Canaccord Genuity Buy $310
Mar-20-24 08:00AM
Mar-17-24 08:50AM
Mar-13-24 07:30AM
Mar-06-24 11:26AM
Mar-05-24 09:06AM
08:27AM Loading…
08:27AM
07:52AM
07:30AM
Feb-27-24 08:30AM
Feb-24-24 08:45AM
Feb-21-24 12:06PM
Feb-16-24 12:08PM
09:46AM
01:55AM
12:02AM
12:39PM Loading…
Feb-15-24 12:39PM
10:30AM
08:37AM
08:17AM
08:00AM
06:54AM
Feb-13-24 07:48PM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
Feb-05-24 05:02PM
Jan-30-24 03:02PM
Jan-29-24 08:00AM
Jan-09-24 08:05AM
Jan-08-24 01:49PM
Jan-07-24 06:00PM
07:30AM Loading…
Jan-02-24 07:30AM
Dec-22-23 02:07AM
Dec-19-23 11:41AM
Dec-13-23 07:30AM
Dec-07-23 07:53PM
Dec-06-23 08:00AM
Nov-30-23 08:00AM
Nov-11-23 04:00PM
Nov-09-23 09:25AM
Nov-08-23 09:55AM
Nov-07-23 08:00AM
Nov-04-23 01:08PM
Nov-03-23 11:47AM
11:06AM
Nov-02-23 10:09AM
10:00AM
08:12AM
08:00AM
Oct-26-23 02:00PM
10:02AM
Oct-25-23 05:19PM
11:05AM
Oct-19-23 07:28PM
10:01AM
08:00AM
Oct-12-23 08:24AM
Oct-10-23 10:24AM
Oct-09-23 04:35PM
04:08PM
10:34AM
10:19AM
07:49AM
07:36AM
07:30AM
Oct-08-23 06:29AM
Oct-06-23 07:00AM
Sep-20-23 12:12PM
Sep-14-23 04:07PM
09:36AM
Sep-13-23 06:24PM
04:57PM
08:08AM
07:00AM
Sep-08-23 09:58AM
06:52AM
Sep-07-23 11:30AM
07:22AM
07:08AM
07:00AM
Sep-06-23 11:30AM
03:00AM
Aug-27-23 09:31AM
Aug-25-23 06:35PM
06:02PM
05:00PM
Aug-15-23 09:15AM
Aug-10-23 06:08AM
Aug-08-23 06:20AM
Aug-06-23 07:26PM
Aug-04-23 11:24AM
09:53AM
Aug-03-23 11:53PM
11:00AM
09:15AM
08:05AM
08:00AM
Aug-02-23 08:30AM
Jul-27-23 05:14AM
Jul-24-23 02:07PM
01:20PM
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHARP PHILLIP ADirectorFeb 29 '24Option Exercise59.2530,0001,777,50030,000Mar 01 04:12 PM
SHARP PHILLIP ADirectorFeb 29 '24Sale151.3430,0004,540,0710Mar 01 04:12 PM
Greenstreet YvonneChief Executive OfficerFeb 28 '24Sale155.312,932455,35748,128Feb 29 04:18 PM
Garg PushkalCMO & EVP Dev & Med AffairsFeb 28 '24Sale155.3057489,1458,666Feb 29 04:17 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerFeb 28 '24Sale155.3057489,14519,478Feb 29 04:18 PM
Tanguler TolgaEVP, Chief Commercial OfficerFeb 28 '24Sale155.3050177,8055,236Feb 29 04:18 PM
Franchini Indrani LallEVP, CLO & SecretaryFeb 28 '24Sale155.3032951,0944,133Feb 29 04:16 PM
Franchini Indrani LallEVP, CLO & SecretaryFeb 27 '24Option Exercise0.0087804,462Feb 29 04:16 PM
Greenstreet YvonneChief Executive OfficerFeb 27 '24Option Exercise0.005,921051,060Feb 29 04:18 PM
Tanguler TolgaEVP, Chief Commercial OfficerFeb 27 '24Option Exercise0.001,66705,737Feb 29 04:18 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerFeb 27 '24Option Exercise0.001,908020,052Feb 29 04:18 PM
Garg PushkalCMO & EVP Dev & Med AffairsFeb 27 '24Option Exercise0.001,90809,240Feb 29 04:17 PM
Greenstreet YvonneChief Executive OfficerFeb 16 '24Sale148.067,0301,040,88545,139Feb 20 04:07 PM
Garg PushkalCMO & EVP Dev & Med AffairsFeb 16 '24Sale148.061,308193,6667,332Feb 20 04:09 PM
Tanguler TolgaEVP, Chief Commercial OfficerFeb 16 '24Sale148.061,009149,3974,070Feb 20 04:08 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerFeb 16 '24Sale148.061,007149,09918,144Feb 20 04:08 PM
Franchini Indrani LallEVP, CLO & SecretaryFeb 02 '24Sale170.991,591272,0503,584Feb 05 04:05 PM
Franchini Indrani LallEVP, CLO & SecretaryFeb 01 '24Option Exercise0.005,17505,175Feb 05 04:05 PM
BONNEY MICHAEL WDirectorDec 27 '23Option Exercise96.4530,0002,893,50046,029Dec 29 04:03 PM
BONNEY MICHAEL WDirectorDec 27 '23Sale195.0030,0005,850,00016,029Dec 29 04:03 PM
Garg PushkalCMO & EVP Dev & Med AffairsAug 07 '23Sale183.894,166766,0834,345Aug 07 06:05 PM
Vaishnaw AkshayPresidentAug 04 '23Sale185.854,057753,98622,774Aug 07 06:04 PM
Greenstreet YvonneChief Executive OfficerAug 04 '23Sale185.854,057753,98635,216Aug 07 06:04 PM
Garg PushkalCMO & EVP Dev & Med AffairsAug 04 '23Sale185.853,461643,2238,511Aug 07 06:05 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerAug 04 '23Sale185.853,460643,03715,873Aug 07 06:05 PM
BONNEY MICHAEL WDirectorAug 03 '23Sale185.386,4481,195,31016,029Aug 04 04:02 PM
BONNEY MICHAEL WDirectorAug 02 '23Option Exercise0.0022,477022,477Aug 04 04:02 PM
Garg PushkalCMO & EVP Dev & Med AffairsApr 28 '23Sale199.022,455488,5954,345Apr 28 05:54 PM
Greenstreet YvonneChief Executive OfficerApr 27 '23Sale194.597,6151,481,81130,332Apr 28 05:55 PM
Vaishnaw AkshayPresidentApr 27 '23Sale194.592,392465,46417,890Apr 28 05:54 PM
Garg PushkalCMO & EVP Dev & Med AffairsApr 27 '23Sale194.591,839357,8556,800Apr 28 05:54 PM
Tanguler TolgaEVP, Chief Commercial OfficerApr 27 '23Sale194.591,476287,2151,801Apr 28 05:55 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerApr 27 '23Sale194.59977190,11311,706Apr 28 05:55 PM
Franchini Indrani LallEVP, CLO & SecretaryApr 06 '23Sale210.003,500735,0000Apr 10 04:29 PM